Provention Bio price target lowered to $16 from $18 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Provention Bio to $16 from $18 and keeps a Buy rating on the shares. The target is lowered to reflect the impact of the dilution from the issuance of stock to Sanofi, the analyst tells investors in a research note.